 Kala Pharmaceuticals Inc NASDAQ: KALA has acquired Combangio Inc, a private company developing regenerative biotherapies for severe ocular surface diseases. Combangio is developing CMB-012, a secretome therapy, to address the complex wound healing process in persistent corneal epithelial defect PCED and other severe ocular diseases driven by impaired corneal healing. 